Valtecne (VLT) H1 2024 earnings summary

Executive summary

• H1 2024 revenues were €17.1M (+0.4% YoY), with a strategic shift toward the medical segment, now 68.3% of sales (+15.7% YoY), offsetting a 21.9% decline in industrial revenues.

• Adjusted EBITDA was €4.4M (-5.4% YoY), with margin on value of production improving to 27.7%; reported EBITDA margin rose to 23.7%.

• Net profit was €2.2M, down 7% YoY, in line with the decrease in value of production.

• Net cash position improved to €4.4M (from €2.4M at 31/12/2023), supporting future M&A ambitions.

• Equity increased by 11.1% to €21.9M compared to FY 2023.

Financial highlights

• Revenues stable at €17.1M (+0.4% YoY); value of production fell 7.4% to €15.9M.

• Adjusted EBITDA margin improved to 27.7% (from 27.1%); reported EBITDA margin rose to 23.7%.

• Net profit margin slightly increased to 13.8% (from 13.7%).

• Net financial position improved to €4.4M cash positive, up €2M from FY 2023.

• Capex focused on production assets; tangible fixed assets up 7.4% to €7.66M.

Outlook and guidance

• Medical business expected to remain strong, supported by robust order backlog and customer base expansion.

• Industrial business anticipated to stay flat or weak, with European market weakness offset by stable demand from American OEMs.

• Full-year 2024 results expected to be broadly in line with 2023.

• M&A activity, particularly targeting medical contract manufacturers, is a strategic priority with ample liquidity.